11 research outputs found
Carvedilol for prevention of restenosis after directional coronary atherectomy : final results of the European carvedilol atherectomy restenosis (EUROCARE) trial
BACKGROUND: In addition to its known properties as a competitive,
nonselective beta and alpha-1 receptor blocker, carvedilol directly
inhibits vascular myocyte migration and proliferation and exerts
antioxidant effects that are considerably greater than those of vitamin E
or probucol. This provides the basis for an evaluation of carvedilol for
the prevention of coronary restenosis. METHODS AND RESULTS: In a
prospective, double-blind, randomized, placebo-controlled trial, 25 mg of
carvedilol was given twice daily, starting 24 h